MDS to sell pharma unit for $50M

Canadian health sciences company MDS Incsaid is selling its late-stage pharma services unit to INC Research for $50 million. The unit--which covers Phase II to IV development--employs 800 workers and conducts trials in more than 25 countries. Report

Suggested Articles

It’s final: England won’t be covering AZ’s quick-selling Tagrisso in previously untreated non-small cell lung cancer patients with EGFR mutatations.

Top J&J meds have managed to hang onto market share in the face of new generics and biosims, but the drugmaker expects the pain to continue in 2020.

Lonza’s search for a new CEO is expected to be wrapped up this year as the CDMO homes in on a list of veterans from outside the company.